T.G. SAKOVETS

Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

 Sakovets T.G. ― Cand. Med. Sc., Associate Professor of the Department of Neurology and Rehabilitation, tel. +7-909-307-94-77, e-mail: [email protected]

 The prevalence of Sjogren’s disease is estimated at about 0.6%, while 40% of all cases is secondary Sjogren disease in patients with systemic lupus erythematosus, systemic scleroderma, or rheumatoid arthritis. Extraglandular manifestations of Sjogren’s disease are detected in one third of patients and are represented by arthritis, Raynaud’s phenomenon, lymphadenopathy, vasculitis, interstitial pneumonia, malignant lymphoma, disorders of the genitourinary and neurologic systems. More rare manifestations include meningitis, myelopathy, progressive multiple sclerosis, pseudo-tumoral lesions. The prevalent types of neuropathy in Sjogren’s disease are sensory and sensory-motor forms. There are various forms of peripheral neuropathy associated with Sjogren disease, including sensory atactic neuropathy, painful sensory neuropathy without sensory ataxia, neuropathy of the trigeminal nerve, multiple mononeuropathy, multiple cranial neuropathy, radiculoneuropathy and autonomic neuropathy with anhydrosis. Given the frequent occurrence of disability in patients with lesions of the nervous system in primary and secondary Sjogren’s disease, the doctors of various specialities should be aware about this disease.

Key words: Sjogren’s disease, neuropathy.

REFERENCES

1. Helmick C.G., Felson D.T., Lawrence R.C. et al. Estimates of the prevalence ofarthritis and other rheumatic conditions in the United States. Arthritis Rheum, 2008, no. 58, rr. 15-25.
2. Carsons S. Sjo¨gren’s syndrome. In: Harris E.D., Budd R.C., Genovese M.C. et al., editors. Kelly’s textbook of rheumatology. Philadelphia: Elsevier Saunders, 2005. 1105 p.
3. Segal B., Walk D. Involvement of nervous system pathways in primary Sj˛gren’s syndrome. Rheum. Dis. Clin. N. Am, 2008, no. 34, rr. 885-906.
4. Vitali C., Bombardieri S., Jonsson R. et al. Classification criteria for Sjo¨gren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann. Rheum. Dis, 2002, no. 61, rr. 544-548.
5. Szanto A., Szodoray P., Kiss E. et al. Clinical, serologic, and genetic profiles of patients with associated Sjo¨gren’s syndrome and systemic lupus erythematosus. Hum. Immunol, 2006, no. 67, rr. 924-930.
6. Eystathioy T., Chan E.K., Tenebaum S.A. et al. A phosphorylated cytoplasmic autoantigen, GW 182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol. Biol. Cell, 2002, no. 13, rr. 1338-1351.
7. Eystathioy T., Chan E.K., Takeuchi K. et al Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182. J. Mol. Med. (Berlin, Germany), 2003, no. 81, rr. 811-815.
8. Murata Y., Maeda K., Kawai H. et al. Antiganglion neuron antibodies correlate with neuropathy in Sjogren’s syndrome. Neuroreport, 2005, no. 16, rr. 677-680.
9. Nanji R.A., Eystathioy T., Chan E.K. et al. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin. Immunol. (Orlando Fla), 2007, no. 125, rr. 247-256.
10. Michel L., Toulgoat F., Desal H. et al. Atypical neurologic complications in patients with primary sjögren’s syndrome: report of 4 sases. Semin. Arthritis Rheum, 2011, no. 40, rr. 338-342.
11. Harboe E., Tjensvoll A.B., Maroni S. et al Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjogren syndrome: a comparative population-based study. Ann. Rheum. Dis, 2009, no. 68, rr. 1541-1546.
12. Vitale C., Palombi G., Cataleta P. Treating Sjogren’s syndrome: insights for the clinician. Ther. Adv. Musculoskelet. Dis, 2010, no. 2, rr. 155-166.
13. Hughes R.A., Donofrio P., Bril V. et al. Intravenous immuneglobulin (10% caprylate-chromatography purified) for the treatment of shronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebo-controlled trial. Lancet Neurol, 2008, no. 7, rr. 136-144.
14. Pavlakis P.P., Alexopoulos H., Kosmidis M.L. et al. Peripheral neuropathies in Sjögren’s syndrome: A critical update on clinical features and pathogenetic mechanisms. Journal of Autoimmunity, 2012, no. 39, rr. 27-33.
15. Fox R.I. Sjogren’s syndrome. Lancet, 2005, no. 366, pp. 321-324.
16. Terrier B., Lacroix C., Guillevin L. et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjogren’s syndrome-related neuropathy. Arthritis Rheum, 2007, no. 57, rr. 1520-1529.
17. Morozumi S., Kawagashira Y., Iijima M. et al. Intravenous immunoglobulin treatment for rainful sensory neuropathy associated with Sjogren’s syndrome. J. Neurol. Sci, 2009, no. 279, rr. 57-61.
18. Schaublin G.A., Michet J.C., Dyck P.J. et al. An update on the classification and treatment of vasculitic neuropathy. Lancet Neurol, 2005, no.4, rr. 853-865.
19. Mori K., Iijima M., Koike H. et al. Sjogren’s syndrome associated painful sensory neuropathy without sensory ataxia. J. Neurol. Neurosurg. Psychiatry, 2003, no. 74, rr. 1320-1322.
20. Sghirlanzoni A., Pareyson D., Lauria G. Sensory neuron diseases. Lancet Neurol, 2005, no. 4. , rr. 349-361.
21. Dworkin R.H., O’Connor A.B., Backonja M. et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain, 2007, no. 132, rr. 237-251.
22. Briani C. MRI evidence of trigeminal sensory neuropathy in Sjögren’s Syndrome / Letters to the Editor. Clinical Neurophysiology, 2013, no. 124, pp. 1700-1706.
23. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum, 2002, no. 46, rr. 741-747.
24. Spies J.M. The spectrum of autonomic failure associated with Sjogren’s syndrome/Abstracts. Journal of Clinical Neuroscience, 2007, no. 14, pp. 1009-1040.
25. Sene D., Jallouli M., Lefaucheur J.P. et al. Peripheral neuropathies associated with primary Sjogren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine, 2011, no. 90, rr. 133-138.
26. Omdal R., Mellgren S.I., Goransson L.G. Small nerve fiber involvement in systemic lupus erythematosus: a controlled study. Arthritis Rheum, 2002, no. 46, rr. 1228-1232.
27. Rist S., Sellam J., Hachulla E. et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren’s syndrome: a national multicentric retrospective study. Arthritis Care Res, 2011, no. 63, rr. 1339-1344.
28. Birnbaum J. Peripheral nervous system manifestations of Sjogren syndrome. Neurologist, 2010, no. 16, rr. 287-297.
29. Mandel S., Lopinto-Khoury C., Manon-Espaillat R. et al. Evaluation and management of the neurological manifestations of Sjogren’s syndrome. In: Wallace D, editor. The Sjogren’s book. 4th edition. New York: Oxford: Chapter 26, 2012. Pp. 249-259.
30. Mekinian A., Ravaud P., Hatron P. et al. Efficacy of rituximab in primary Sjogren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann. Rheum. Dis, 2012, no. 71, rr. 84-87.
31. Bourcier M., Vinik A.A. 41-year-old man with polyarthritis and severe autonomic neuropathy. Ther. Clin. Risk Manag, 2008, no. 4, rr. 837-842.
32. Agmon-Levin N., Kivity S., Tzioufas A.G. et al. Low levels of vitamin D are associated with neuropathy and lymphoma among patients with Sjögren’s syndrome. Journal of Autoimmunity, 2012, no. 39, pp. 234-239.
33. Aljanob I.H., Sabharwal A., Krishnakumar B. et al. Is it Sjögren’s syndrome or burning mouth syndrome? Distinct pathoses with similar oral symptoms. Oral and maxillofacial pathology, 2017, vol. 123, no. 4, rr. 482-495.